Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aristeromycin SCHEMBL10353292 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL12280589 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL10353291 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL14515457 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL12173988 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL7534801 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL9820408 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL12157242 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL692209 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL15297972 | 0.99 | AHCY (0.97) | AHCYADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435088-B2 | Salicyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250093263-A1 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION | 2025-03-20 | — | — | US | disclosed |
| EP-4374157-A2 | FRET-BASED ASSAYS | The General Hospital Corporation (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117797146-A | SARM1 enzyme activity inhibitors and their use in neurodegenerative diseases | 科辉智药生物科技（无锡）有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023205272-A1 | PYRAZINAMIDE COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230233497-A1 | COMPOSITION FOR POLYAMINE BIOSYNTHESIS | BM HEALTH GMBH (AT) | 2023-07-27 | — | — | US | disclosed |
| CN-115814270-A | Electrical stimulator | 中国科学院深圳理工大学(筹) | 2023-03-21 | — | — | CN | disclosed |
| WO-2023004438-A2 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-4114380-A1 | COMPOSITION FOR POLYAMINE BIOSYNTHESIS | BM Health GmbH (AT) | 2023-01-11 | — | — | EP | disclosed |
| EP-4100112-A1 | FUNCTION OPTIMIZATION ALGORITHM AND MULTI-TYPE ELECTROTHERAPY COMBINATION TREATMENT | Malter, Richard (AU) | 2022-12-14 | — | — | EP | disclosed |
| US-20220387796-A1 | ELECTRICAL STIMULATION METHOD FOR MEDICAL TREATMENT | MALTER RICHARD (AU) | 2022-12-08 | — | — | US | disclosed |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ADSL, SLC35B2, ADORA1 | AHCY 44/4885ADORA2B 10/4885 |
| US-12435088-B2 | Salicyl-adenosinemonosulfamate analogs and uses thereof | ADSL, SLC35B2, ADORA1 | AHCY 44/4885ADORA2B 10/4885 |
| US-20250093263-A1 | FRET-BASED ASSAYS | TARBP1, GTPBP4, TERF2IP | AHCY 818/4885ADORA2B 2861/4885 |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | PC, GOT2, PCK2 | AHCY 2564/4885ADORA2B 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.